Clinical Study To Evaluate The Performance And Safety Of Favipiravir in COVID-19
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Study Evaluating the Efficacy and Safety of Favipiravir in the Treatment of Patients With COVID-19-Moderate Type
Sponsor: Giuliano Rizzardini
Listed as NCT04336904, this PHASE3 trial focuses on COVID-19 and remains ongoing. Sponsored by Giuliano Rizzardini, it has been updated 6 times since 2020, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
May 2022 — Jul 2024 [monthly]
Unknown Status PHASE3
Status: Active Not Recruiting → Unknown Status
-
Jan 2021 — May 2022 [monthly]
Active Not Recruiting PHASE3
▶ Show 1 earlier version
-
May 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
First recorded
Mar 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Giuliano Rizzardini
For direct contact, visit the study record on ClinicalTrials.gov .